Enzyme-Linked Immunosorbent Assay Detection For Malignancy Using Anti-P53 Antibodies
https://doi.org/10.37268/mjphm/vol.21/no.1/art.789
- Author:
MUHANNA ALSHAIBANI
1
;
Radin Maya Saphira Radin Mohamed
1
;
Ishak Mat
2
;
Adel AlGheethi
1
;
Jacinta Santhanam
3
Author Information
1. Micro-pollutant Research Centre (MPRC), Department of Water and Environmental Engineering, Faculty of Civil Engineering and Built Environment, Universiti Tun Hussein Onn Malaysia, 86400 Parit Raja, Johor, Malaysia.
2. Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bandar Putra Bertam, Kepala Batas, Penang 13200, Malaysia.
3. Centre for Toxicology and Health Risk Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia.
- Publication Type:Journal Article
- Keywords:
p53 gene, serum anti-p53 antibodies, ELISA, malignant tumours, Natural autoantibodies
- From:Malaysian Journal of Public Health Medicine
2021;21(1):208-215
- CountryMalaysia
- Language:English
-
Abstract:
Tumour protein 53 (p53) plays an important role in the instruction of the cell cycle. In a variety of transformed cell lines, tumour protein is expressed in high amounts, and it is believed to contribute to transformation and malignancy. This research aimed to detect the anti-p53 antibodies in sera of patients with various malignant tumours and to evaluate the sensitivity and specificity of an enzyme-linked immunosorbent assay (ELISA). A case-control study was conducted on samples from 49 patients with various types of malignant tumours at Sultanah Bahiyah Hospital, Alor Setar, Kedah, Malaysia, and 32 healthy control cases with non‐malignant disease collected from Universiti Sains Malaysia clinic, Penang, Malaysia. The antibodies against p53 protein in the serum samples were analysed using the commercial ELISA kit, Calbiochem® p53- ELISAPLUS. The results showed that the rate of anti-p53 antibodies in patients with various malignant tumours was 13 out of 49 (26.5 %), compared with only 2 out of 32 (6.25%) in healthy controls (p < 0.001). The sensitivity of this kit reached 28.6% and the specificity was 93.8%. In conclusion, these results suggest that the anti-p53 antibodies can be detected in different sera of malignant tumour patients and the ELISA kit is highly specific; nevertheless, its discrimination power is not perfect because of its low sensitivity to determine the anti-p53 antibodies.
- Full text:22.2021my0588.pdf
